**8. Chemotherapy**

The use of treatments with drugs capable of penetrating and collapsing hepatic hydatid cysts is reported in numerous publications. These drugs are prescribed alone or together with surgery and less-invasive therapies such as PAIR. Currently, albendazole has shown effectiveness in reducing the size or even causing the death of the parasite. For this reason, it is employed to prevent recurrence after surgery. It is also used as the only therapy in patients who refuse surgery or who are inoperable due to disseminated

**167**

*Surgical Treatment of Hepatic Hydatidosis DOI: http://dx.doi.org/10.5772/intechopen.86319*

**Author details**

**9. Conclusion**

Cesar Muñoz Castro4,5, Marcelo Klein Diaz6

Hospital Dr. Hernán Henríquez, Temuco, Chile

Hospital Regional, Talca, Chile

Temuco, Chile

Temuco, Chile

1 Hepatobiliopancreatic Surgery Unit, Surgery Service,

3 Surgery Department, Clínica Alemana de Temuco, Chile

\*Address all correspondence to: luis.burgos.s@ufrontera.cl

provided the original work is properly cited.

2 Surgery Department, Universidad de la Frontera, Temuco, Chile

Luis Burgos San Juan1,2,3\*, Hector Losada Morales1,2,3, Jorge Silva Abarca1,2,3,

hydatidosis or because of other comorbidities [58]. In Chile, it is indicated preoperatively in doses of 10 mg/kg of weight for one cycle of 14 or 21 days and postoperatively from one to three cycles according to eventual appearance of hepatic dysfunction.

Hepatic hydatidosis is still a disease that spreads without epidemiological control in many parts of the world. Also, a continuous biological adaptation of the parasite to subsist in the intermediate host has been demonstrated, which would explain the great difficulties in eradicating this zoonosis. The permanent and even increasing incidence of this disease determines very high health costs necessary to treat patients, sometimes with complex pathological presentations. Efforts are being made to find new alternatives to diagnose early stages of the parasitosis. The creation of new vaccines with the intention of immunizing the intermediate host would determine a better control of human hydatidosis. Surgical advances are allowing for more and more radical surgical procedures with acceptable rates of morbidity and mortality. However, the implementation of minimally invasive surgeries presents significantly higher costs. Logic would dictate that the best path is to minimize the number of new patients affected through successful epidemiological control.

4 Digestive Surgery and Hepatobiliopancreatic Surgery Unit, Surgery Service,

6 Interventional Radiology Unit, Imaging Service, Hospital Dr. Hernán Henríquez,

7 Pathological Anatomy Department, Hospital Dr. Hernán Henríquez Aravena,

© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium,

5 Department of Surgery, Universidad Católica del Maule, Talca, Chile

and Pablo Guzmán González7

hydatidosis or because of other comorbidities [58]. In Chile, it is indicated preoperatively in doses of 10 mg/kg of weight for one cycle of 14 or 21 days and postoperatively from one to three cycles according to eventual appearance of hepatic dysfunction.
